Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.40), $0.02 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.17 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance
• Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance